Teriparatide
Active ingredient: Teriparatide
In short: Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy.
What is Teriparatide used for?
Teriparatide injection is indicated:
For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebral and nonvertebral fractures.
To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
Teriparatide dosage
The recommended dosage is 20 mcg given subcutaneously once a day. Instruct patients to take supplemental calcium and vitamin D if daily dietary intake is inadequate.
Administer teriparatide injection as a subcutaneous injection into the thigh or abdominal region. Teriparatide injection is not approved for intravenous or intramuscular use.
Teriparatide injection should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur .
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration (teriparatide injection is a clear and colorless liquid). Do not use if solid particles appear or if the solution is cloudy or colored.
Patients and/or caregivers who administer teriparatide injection should receive appropriate training and instruction on the proper use of the teriparatide injection delivery device from a qualified health professional.
Use of teriparatide for more than 2 years during a patient's lifetime should only be considered if a patient remains at or has returned to having a high risk for fracture .
How to take Teriparatide — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Medication Guide and the User Manual) before starting teriparatide injection and each time the prescription is renewed. Failure to follow the instructions may result in inaccurate dosing.
Hypersensitivity Reactions
Advise patients that serious hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, can occur with teriparatide injection. Advise patients to discontinue teriparatide injection and promptly seek medical attention if signs or symptoms of hypersensitivity reactions occur .
Osteosarcoma
Patients should be made aware that in rats, teriparatide caused an increase in the incidence of osteosarcoma (a malignant bone tumor). Although cases of osteosarcoma have been reported in patients using teriparatide, no increased risk of osteosarcoma was observed in adult humans treated with teriparatide .
Hypercalcemia
Instruct patients taking teriparatide injection to contact a health care provider if they develop persistent symptoms of hypercalcemia (e.g., nausea, vomiting, constipation, lethargy, muscle weakness) . …
Warnings & precautions
Do not take this medicine if: Teriparatide injection is contraindicated in patients with a history of severe hypersensitivity to teriparatide or any of the inactive ingredients of teriparatide injection. Reactions have included anaphylaxis and angioedema .
Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported in patients treated with parathyroid hormone (PTH) analogs, including teriparatide injection . If signs or symptoms of a hypersensitivity reaction occur, discontinue treatment with teriparatide injection, initiate appropriate supportive care, and monitor until signs and symptoms resolve. Discontinue teriparatide injection permanently in patients with a severe hypersensitivity reaction to teriparatide injection. Teriparatide injection is contraindicated in patients with a history of severe hypersensitivity to teriparatide or any of the inactive ingredients of teriparatide injection .
An increase in the incidence of osteosarcoma (a malignant bone tumor) was observed in male and female rats treated with teriparatide. Osteosarcoma has been reported in patients treated with teriparatide in the post marketing setting; however, an increased risk of osteosarcoma has not been observed in observational studies in humans. There are limited data assessing the risk of osteosarcoma beyond 2 years of teriparatide use .
Avoid teriparatide injection use in patients with (these patients are at increased baseline risk of osteosarcoma):
Open epiphyses (pediatric and young adult patients) (teriparatide injection is not approved in pediatric patients) .
Metabolic bone diseases other than osteoporosis, including Paget's disease of the bone.
Bone metastases or a history of skeletal malignancies.
Prior external beam or implant radiation therapy involving the skeleton.
Hereditary disorders predisposing to osteosarcoma. …
Teriparatide side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypersensitivity Reactions
Osteosarcoma
Hypercalcemia and Cutaneous Calcification
Risk of Urolithiasis
Orthostatic Hypotension
Risk of Digoxin Toxicity
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Men with Primary or Hypogonadal Osteoporosis and Postmenopausal Women with Osteoporosis
The safety of teriparatide in the treatment of osteoporosis in men and postmenopausal women was assessed in two randomized, double-blind, placebo-controlled trials of 1382 patients (21% men, 79% women) aged 28 to 86 years (mean 67 years) . The median durations of the trials were 11 months for men and 19 months for women, with 691 patients exposed to teriparatide and 691 patients to placebo. All patients received 1000 mg of calcium plus at least 400 IU of vitamin D supplementation per day.
The incidence of all-cause mortality was 1% in the teriparatide group and 1% in the placebo group. The incidence of serious adverse events was 16% in the teriparatide group and 19% in the placebo group. Early discontinuation due to adverse events occurred in 7% in the teriparatide group and 6% in the placebo group. …
Drug interactions
Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity. Teriparatide may transiently increase serum calcium. Consider the potential onset of signs and symptoms of digitalis toxicity when teriparatide injection is used in patients receiving digoxin .
About this medicine
Teriparatide injection is a recombinant human parathyroid hormone analog (PTH 1-34). It has an identical sequence to the 34 N‑terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone.
The molecular formula of teriparatide is C181H291N55O51S2 and the molecular weight is 4117.8 daltons. Its amino acid sequence is shown below:
Teriparatide is manufactured using a strain of Pseudomonas fluorescens modified by recombinant DNA technology. Teriparatide injection is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a single-patient-use delivery device (pen) for subcutaneous injection. Each pen is filled with volume to allow delivery of 2.24 mL. Each mL contains 250 mcg teriparatide (as a free base), 0.41 mg glacial acetic acid, 0.10 mg sodium acetate, 45.4 mg mannitol, 3 mg metacresol, and water for injection. The drug product is a pH 4.0 solution.
Each cartridge, pre-assembled into a delivery device, delivers 20 mcg of teriparatide per dose each day for up to 28 days. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1b007339-dd0d-f019-5e0a-9b1b0f75011c. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone